Cardene is a medicinal drug owned by Chiesi and was first authorized for market use on 30 January, 1992. It is usually offered in injectable forms. The active ingredient in Cardene is nicardipine hydrochloride. The product is protected by a total of 6 patents, none of which have expired yet.
The generic version of Cardene is expected to be available after 26 December, 2027. This is when the last patent protecting this drug is set to expire, leaving room for generic competitors to enter the market.
Cardene, with its active ingredient nicardipine hydrochloride, is often utilized as a method for treating acute elevations of blood pressure in human patients who need such treatment.
Cardene is protected by a series of 6 patents. The latest patent protecting Cardene generic is due to expire on December 26, 2027. Below are the details of the patent: